File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Primary treatment with vincristine, dactinomycin, and cyclophosphamide in nondysgerminomatous germ cell tumor of the ovary

TitlePrimary treatment with vincristine, dactinomycin, and cyclophosphamide in nondysgerminomatous germ cell tumor of the ovary
Authors
Issue Date1989
PublisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/ygyno
Citation
Gynecologic Oncology, 1989, v. 34 n. 2, p. 155-158 How to Cite?
AbstractThirty-three patients with malignant nondysgerminomatous germ cell tumors were treated with vincristine/dactinomycin/cyclophosphamide regimen. Thirty-two patients were suitable for analysis. The overall cure rate was 68.7%. This is comparable to the cure rate observed in the cisplatin/vinblastin/bleomycin regimen. The roles of second-look laparotomy in malignant germ cell tumor are discussed.
Persistent Identifierhttp://hdl.handle.net/10722/173141
ISSN
2015 Impact Factor: 4.198
2015 SCImago Journal Rankings: 2.284
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWong, LCen_US
dc.contributor.authorNgan, HYSen_US
dc.contributor.authorMa, HKen_US
dc.date.accessioned2012-10-30T06:28:08Z-
dc.date.available2012-10-30T06:28:08Z-
dc.date.issued1989en_US
dc.identifier.citationGynecologic Oncology, 1989, v. 34 n. 2, p. 155-158en_US
dc.identifier.issn0090-8258en_US
dc.identifier.urihttp://hdl.handle.net/10722/173141-
dc.description.abstractThirty-three patients with malignant nondysgerminomatous germ cell tumors were treated with vincristine/dactinomycin/cyclophosphamide regimen. Thirty-two patients were suitable for analysis. The overall cure rate was 68.7%. This is comparable to the cure rate observed in the cisplatin/vinblastin/bleomycin regimen. The roles of second-look laparotomy in malignant germ cell tumor are discussed.en_US
dc.languageengen_US
dc.publisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/ygynoen_US
dc.relation.ispartofGynecologic Oncologyen_US
dc.subject.meshAdulten_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Adverse Effects - Therapeutic Useen_US
dc.subject.meshCyclophosphamide - Administration & Dosageen_US
dc.subject.meshDactinomycin - Administration & Dosageen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHumansen_US
dc.subject.meshOvarian Neoplasms - Drug Therapyen_US
dc.subject.meshTeratoma - Drug Therapyen_US
dc.subject.meshVincristine - Administration & Dosageen_US
dc.titlePrimary treatment with vincristine, dactinomycin, and cyclophosphamide in nondysgerminomatous germ cell tumor of the ovaryen_US
dc.typeArticleen_US
dc.identifier.emailNgan, HYS:hysngan@hkucc.hku.hken_US
dc.identifier.authorityNgan, HYS=rp00346en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/0090-8258(89)90132-7-
dc.identifier.pmid2753421-
dc.identifier.scopuseid_2-s2.0-0024372453en_US
dc.identifier.volume34en_US
dc.identifier.issue2en_US
dc.identifier.spage155en_US
dc.identifier.epage158en_US
dc.identifier.isiWOS:A1989AG45100006-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridWong, LC=7402092003en_US
dc.identifier.scopusauthoridNgan, HYS=34571944100en_US
dc.identifier.scopusauthoridMa, HK=7403095603en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats